Inhibition of human immunodeficiency virus type-1 by cdk inhibitors

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Guendel, Irene ^a,b   Agbottah, Emmanuel T ^a   Kehn Hall, Kylene ^b   Kashanchi, Fatah ^a,b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINOPURINE; 2,6 DICHLOROPURINE; 5' IODO INDIRUBIN 3' MONOXIME; 6 BENZYLOXYPURINE; 6 N,N DIMETHYLADENINE; 9 CYANOPAULLONE; ALOISINE A; ALSTERPAULLONE; CASPASE 3; CGP 74514A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVONE; INDIRUBIN 3' MONOXIME; INDIRUBIN 3' MONOXIME 5' SULFONIC ACID; ISO OLOMOUCINE; KENPAULLONE; N 6 (DELTA2 ISOPENTENYL)ADENINE; N9 ISOPROPYLOLOMOUCINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLOMOUCINE; PAULLONE; PURVALANOL A; ROSCOVITINE; SC 514; UNCLASSIFIED DRUG; WHI P 180;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME REPRESSION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION; WESTERN BLOTTING;

EID: 77952932797     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-7     Document Type: Article

References (57)

1. Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 2002, 8:673-680. 10.1038/nm0702-673, 12091904.
2. Karn J. Tackling Tat. J Mol Biol 1999, 293:235-254. 10.1006/jmbi.1999.3060, 10550206.
3. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000, 20:2629-2634. 10.1128/MCB.20.8.2629-2634.2000, 85478, 10733565.
4. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, Groudine M, Emerman M. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci USA 1994, 91:3862-3866. 10.1073/pnas.91.9.3862, 43682, 8171003.
5. Antoni BA, Stein SB, Rabson AB. Regulation of human immunodeficiency virus infection: implications for pathogenesis. Adv Virus Res 1994, 43:53-145. full_text, 8191958.
6. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, Lowe AD, Singh M, Skinner MA, Valerio R. Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proc Natl Acad Sci USA 1989, 86:6925-6929. 10.1073/pnas.86.18.6925, 297963, 2476805.
7. Feng S, Holland EC. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 1988, 334:165-167. 10.1038/334165a0, 3386755.
8. Weeks KM, Crothers DM. RNA recognition by Tat-derived peptides: interaction in the major groove?. Cell 1991, 66:577-588. 10.1016/0092-8674(81)90020-9, 1907891.
9. Weeks KM, Crothers DM. RNA binding assays for Tat-derived peptides: implications for specificity. Biochemistry 1992, 31:10281-10287. 10.1021/bi00157a015, 1384694.
10. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995, 69:1612-1620. 188757, 7853496.
11. Baskaran R, Dahmus ME, Wang JY. Tyrosine phosphorylation of mammalian RNA polymerase II carboxyl-terminal domain. Proc Natl Acad Sci USA 1993, 90:11167-11171. 10.1073/pnas.90.23.11167, 47943, 7504297.
12. Zhang J, Corden JL. Phosphorylation causes a conformational change in the carboxyl-terminal domain of the mouse RNA polymerase II largest subunit. J Biol Chem 1991, 266:2297-2302.
13. Boeing S, Rigault C, Heidemann M, Eick D, Meisterernst M. RNA polymerase II C-terminal heptarepeat domain Ser-7 phosphorylation is established in a mediator-dependent fashion. J Biol Chem 2010, 285(1):188-196. 10.1074/jbc.M109.046565, 19901026.
14. Meinhart A, Cramer P. Recognition of RNA polymerase II carboxy-terminal domain by 3'-RNA-processing factors. Nature 2004, 430(6996):223-226. 10.1038/nature02679, 15241417.
15. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998, 92:451-462. 10.1016/S0092-8674(00)80939-3, 9491887.
16. Yang X, Gold MO, Tang DN, Lewis DE, Aguilar-Cordova E, Rice AP, Herrmann CH. TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci USA 1997, 94:12331-12336. 10.1073/pnas.94.23.12331, 24930, 9356449.
17. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, Amendt B, Mathews MB, Price DH. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997, 11:2622-2632. 10.1101/gad.11.20.2622, 316609, 9334325.
18. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 1998, 17:7056-7065. 10.1093/emboj/17.23.7056, 1171053, 9843510.
19. Garber ME, Wei P, KewalRamani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev 1998, 12:3512-3527. 10.1101/gad.12.22.3512, 317238, 9832504.
20. Isel C, Karn J. Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J Mol Biol 1999, 290:929-941. 10.1006/jmbi.1999.2933, 10438593.
21. Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol 2000, 20:6958-6969. 10.1128/MCB.20.18.6958-6969.2000, 88771, 10958691.
22. Akoulitchev S, Makela TP, Weinberg RA, Reinberg D. Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature 1995, 377:557-560. 10.1038/377557a0, 7566158.
23. Lu H, Zawel L, Fisher L, Egly JM, Reinberg D. Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II. Nature 1992, 358:641-645. 10.1038/358641a0, 1495560.
24. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH, Brady JN. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol 2000, 20:5077-5086. 10.1128/MCB.20.14.5077-5086.2000, 85957, 10866664.
25. Obeyesekere MN, Herbert JR, Zimmerman SO. A model of the G1 phase of the cell cycle incorporating cyclin E/cdk2 complex and retinoblastoma protein. Oncogene 1995, 11:1199-1205.
26. Clark E, Santiago F, Deng L, Chong S, de La Fuente C, Wang L, Fu P, Stein D, Denny T, Lanka V, et al. Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. J Virol 2000, 74:5040-5052. 10.1128/JVI.74.11.5040-5052.2000, 110856, 10799578.
27. Duan L, Ozaki I, Oakes JW, Taylor JP, Khalili K, Pomerantz RJ. The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol 1994, 68:4302-4313. 236353, 8207805.
28. de la Fuente C, Maddukuri A, Kehn K, Baylor SY, Deng L, Pumfery A, Kashanchi F. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res 2003, 1:131-152. 10.2174/1570162033485339, 15043199.
29. Diwan P, Lacasse JJ, Schang LM. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. J Virol 2004, 78:9352-9365. 10.1128/JVI.78.17.9352-9365.2004, 506918, 15308730.
30. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002, 23:417-425. 10.1016/S0165-6147(02)02071-0, 12237154.
31. Schang LM. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 2004, 1697:197-209.
32. Schang LM, Coccaro E, Lacasse JJ. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes. Nucleosides Nucleotides Nucleic Acids 2005, 24:829-837. 10.1081/NCN-200060314, 16248044.
33. Schang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 2002, 50:779-792. 10.1093/jac/dkf227, 12460995.
34. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2005, 23:9179-9186. 10.1200/JCO.2004.01.0660, 16361620.
35. Schang LM. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr Drug Targets Infect Disord 2005, 5:29-37. 10.2174/1568005053174609, 15777196.
36. Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malim MH, Gray NS, Schaffer PA. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002, 76:7874-7882. 10.1128/JVI.76.15.7874-7882.2002, 136397, 12097601.
37. Milovanceva-Popovska M, Kunter U, Ostendorf T, Petermann A, Rong S, Eitner F, Kerjaschki D, Barnett A, Floege J. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int 2005, 67:1362-1370. 10.1111/j.1523-1755.2005.00213.x, 15780088.
38. Pumfery A, de la Fuente C, Berro R, Nekhai S, Kashanchi F, Chao SH. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des 2006, 12:1949-1961. 10.2174/138161206777442083, 16787240.
39. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 2005, 14:457-477. 10.1517/13543784.14.4.457, 15882121.
40. Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L, Kunick C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem 1999, 42:2909-2919. 10.1021/jm9900570, 10425100.
41. Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 2000, 267:5983-5994. 10.1046/j.1432-1327.2000.01673.x, 10998059.
42. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002, 22:373-384. 10.1002/med.10011, 12111750.
43. Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 1999, 59:2566-2569.
44. Dominguez I, Green JB. Missing links in GSK3 regulation. Dev Biol 2001, 235:303-313. 10.1006/dbio.2001.0317, 11437438.
45. Guendel I, Carpio L, Easley R, Van Duyne R, Coley W, Agbottah E, Dowd C, Kashanchi F, Kehn-Hall K. 9-Aminoacridine inhibition of HIV-1 Tat dependent transcription. Virol J 2009, 6:114. 10.1186/1743-422X-6-114, 2723079, 19630958.
46. Wu W, Kehn-Hall K, Pedati C, Zweier L, Castro I, Klase Z, Dowd CS, Dubrovsky L, Bukrinsky M, Kashanchi F. Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J 2008, 5:41. 10.1186/1743-422X-5-41, 2315641, 18348731.
47. Chugh P, Fan S, Planelles V, Maggirwar SB, Dewhurst S, Kim B. Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol 2007, 366:67-81. 10.1016/j.jmb.2006.11.011, 17157319.
48. Agbottah E, de La Fuente C, Nekhai S, Barnett A, Gianella-Borradori A, Pumfery A, Kashanchi F. Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem 2005, 280:3029-3042. 10.1074/jbc.M406435200, 15531588.
49. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003, 10:1255-1266. 10.1016/j.chembiol.2003.11.010, 14700633.
50. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001, 359:1-16. 10.1042/0264-6021:3590001, 1222116, 11563964.
51. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 2004, 279:49571-49574. 10.1074/jbc.C400442200, 15465828.
52. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 1999, 73:578-586. 10.1046/j.1471-4159.1999.0730578.x, 10428053.
53. Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 2003, 23:9162-9170.
54. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 2005, 25:8375-8385. 10.1523/JNEUROSCI.2164-05.2005, 16162919.
55. Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockestein E, Masliah E. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 2002, 21:493-501. 10.1006/mcne.2002.1196, 12498789.
56. Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, Kovacs AD, Potash MJ, Dewhurst S, Gelbard HA, Maggirwar SB. Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci 2006, 23:2623-2634. 10.1111/j.1460-9568.2006.04813.x, 16817865.
57. Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, Al-Harthi L. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. J Virol 2008, 82:2813-2820. 10.1128/JVI.02498-07, 2258975, 18199649.